Validose, a 10XBeta Venture Studio portfolio company pioneering precision medication delivery, announced recently the closing of a $2 million pre-seed funding round. The funding round was led by Peter Bauer’s Family Office as part of its Technology for Humanity strategy, 10XBeta, and Interstate Fusion Ventures; several angel investors participated.
Validose addresses patient non-adherence in clinical trials—one of the most persistent challenges in drug development—with an innovative approach linking behavior modeling with remote data capture.
This funding round will be used to finalize the development of the company’s ophthalmic solution, a smart-dose eyedropper, which will be launched in Q2 2025.
The Validose platform utilizes an agile dose device, coupled with real-time data delivered to clinicians, to provide a suite of behavioral prompts that can drive patient behavior. The technology was designed to support diverse therapies, including the ophthalmic smart-dose solution, and additional form factors, including a CNS-focused nasal spray device and pill delivery system. This platform delivers objective, precise, and secure real-time adherence data while providing personalized behavioral support to improve patient compliance.
By addressing the critical issue of non-adherence—which contributes to the failure of 30% of drug clinical trials—Validsode aims to dramatically improve clinical trial outcomes and reduce inefficiency in the drug discovery process. Moreover, the company’s solution is especially valuable in trials where non-adherence has high-stakes adverse health effects and patient recruitment poses challenges.
Validose’s approach symbolizes a significant departure from the current market standard, in which non-adherence is poorly tracked or ignored. Currently prevalent approaches require patients to log their adherence in written journal entries or tracking apps, which leads to inconsistent and inaccurate reporting. Unlike traditional systems, Validose integrates with standard drug packaging, providing patients with personalized engagement tools and empowering trial coordinators with actionable insights for timely interventions.
Validose’s platform includes a Dose Exoskeleton, a multi-sensor, adaptable attachment that records adherence metrics across various medication forms. The exoskeleton can be used with nasal spray, ophthalmic drops, and other therapeutic applications, enabling precise tracking and scalability across multiple drug forms.
Validose also features a Patient Portal, which offers personalized dose reminders, real-time messaging, and behavioral coaching. It promotes active patient compliance with motivational prompts to maintain engagement. A Clinician Dashboard provides trial coordinators with real-time adherence insights, enabling them to make timely interventions and optimize trial outcomes through secure, immediate access to patient data.
KEY QUOTES:
“Validose is addressing a critical challenge in drug development: clinical trial failures due to patient non-adherence. Non-adherence significantly raises costs and delays healthcare innovation. While existing solutions offer delayed or passive adherence monitoring, Validose has introduced a proactive, real-time adherence platform that reshapes patient behavior, enhances trial oversight, and accelerates decision-making. We are grateful to our investors for their support as we aim to address a critical healthcare industry challenge, transform clinical trials, and improve drug development.”
- Paul McGrath, CEO of Validose
“At 10XBeta, we are committed to bringing together founders, capital, investors, and talent to launch MedTech solutions that tackle the most significant challenges facing the healthcare industry. Patient non-adherence in clinical trials has long been a costly and time-consuming pain point, leading to failed or delayed drug discovery. We are proud to support Validose in developing cutting-edge technology with the potential to drive significant improvements in clinical trials.”
- Marcel Botha, CEO and Co-Founder of 10XBeta
